Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Grant/Downing, LLC.
Supported by Algeta US, LLC; Bayer HealthCare Pharmaceuticals, Inc; and Janssen Biotech, Inc.
Enduring CME Activity
This activity is an enduring material and consists of a webcast.
Successful completion is achieved by viewing the material, reflecting on its implications in your practice, and completing the assessment component.
- After a passing grade of 75% you will be able to print your certificate.
- The estimated time to complete the activity is 1.5 hours.
- This activity was originally released July 31, 2013 and is eligible for credit through July 31, 2014.
- If you encounter difficulties or need assistance, please call 760-773-4514.
Our policy on privacy - Annenberg Center for Health Sciences respects your privacy. We don’t share information you give us, or have the need to share this information in the normal course of providing the services and information you may request. If there should be a need or request to share this information, we will do so only with your explicit permission. See Privacy Statement and other information at http://www.annenberg.net/privacy-terms.shtml
Contact information - For help or questions about this Internet activity please contact:
8 am – 5 pm, Pacific Time, Monday – Friday
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Novel data presented in this webcast will identify new management strategies for men with advanced and mCRPC involving the urologist. Therapeutic agents with new indications will be reviewed with an overall goal of educating the audience on new pathways to improve patient outcomes. Through interactive real case vignettes, this webcast will explore current clinical issues, best practices, and promising future directions in the treatment of men with mCRPC.
- Evaluate the role of the androgen receptor axis as a target for the treatment of castration-resistant prostate cancer
- Explain clinical data and available therapeutic options, including radioisotopes and other bone targeted agents, for management of bone metastases in patients with CRPC
- Explain the changing role of the urologist in advanced disease
- Discuss the importance of multidisciplinary treatment strategies in the care of patients with advanced CRPC
- Optimize treatment regimens for patients that reflect optimal sequencing of novel hormonal agents, radioisotopes and chemotherapy in the treatment of CRPC
This educational activity is specifically designed for urologists, as well as other healthcare providers interested and/or involved in the treatment of patients with advanced and mCRPC.
Accreditation and Certification
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Annenberg Center for Health Sciences at Eisenhower and Grant/Downing. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
E. David Crawford, MD
Professor of Urology/Surgery/Radiation Oncology
University of Colorado, Denver
Daniel P. Petrylak, MD
Director of Genitourinary Oncology
Yale Cancer Center
Co-director, Signal Transduction Program
New Haven, Connecticut
Neal D. Shore, MD, FACS
Director, CPI, Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina
It is the policy of the Annenberg Center to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.
The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME/CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center policy, the following disclosures have been made:
E. David Crawford, MD
|Research Support:||Precision Biopsy|
Ferring Pharmaceuticals (spouse)
|Daniel P. Petrylak, MD|
Johnson & Johnson
OncoGenex Pharmaceuticals Inc.
Progenics Pharmaceuticals Inc.
Johnson & Johnson
Neal D. Shore, MD, FACS
Astelleas Pharma Inc.
The faculty for this activity have disclosed that there will be discussion about the use of products for non-FDA approved indications.
Additional content planners: In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center policy, the following disclosures have been made.
All staff at the Annenberg Center for Health Sciences at Eisenhower have nothing to disclose.
The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.
This activity is supported by independent educational grants from Algeta US, LLC, Bayer Healthcare Pharmaceuticals, Inc., and Janssen Biotech, Inc.
The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of the commercial supporters, or any other manufacturer of pharmaceuticals, the Annenberg Center for Health Sciences at Eisenhower or Grant/Downing, LLC.
The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult the full prescribing information on any drug presented in this activity for recommended dosage, indications, contra indications, warnings, precautions, and adverse effects before prescribing any medication. This is particularly important when a drug is new or infrequently used.
© 2013 Grant/Downing, LLC
All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage or retrieval systems, without permission in writing from Grant/Downing, LLC.
Browser or device capable of playing streaming audio/video files.